Navigation Links
Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
Date:1/12/2012

nts suffering from a sickle cell crisis. The strong preclinical data suggest that a clinical evaluation of MP4CO in patients could yield meaningful results," said Brian O'Callaghan, President and CEO of Sangart. "Along with our other investigational therapy, MP4OX, we remain committed to developing medicines designed to enhance the delivery of oxygen and other gases to tissues and organs."

Sickle cell disease is an inherited hemoglobin disorder affecting red blood cell circulation in millions of people around the world. People with sickle cell disease have red blood cells that contain mostly hemoglobin S, an abnormal type of hemoglobin. Due to the presence of hemoglobin S, these red blood cells become crescent or sickle-shaped and have difficulty passing through small blood vessels. When sickle-shaped cells block small blood vessels, less blood circulates through the body, causing severe pain and damage to tissues that do not receive a normal blood flow. This vaso-occlusion is known as a "sickle cell crisis".  There are currently no approved medications to treat sickle cell crises, and only symptomatic relief is available.

About MP4
Sangart's product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia. MP4 can bind carbon monoxide for delivery to hemoglobin in red blood cells and heme proteins in tissues to provide anti-inflammatory and anti-apoptotic (anti-programmed cell death) effects. Once carbon monoxide has been released, MP4 takes up oxygen, when circulating through the lung, for delivery to ischemic tissues.

About Sangart<
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
2. Sangart Announces Closing of $50 Million Series G Financing
3. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
4. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
5. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
7. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
9. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
(Date:7/28/2014)... , July 28, 2014  ImaginAb, Inc. today ... Crystal , MD as Vice President of Business Development. ... Development Product Acquisition & Licensing team at G.E. Life ... strategy and partnerships in the precision medicine space will ... biotechnology and pharmaceutical companies across the spectrum to extend ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... , WALTHAM, Mass., Nov. 17 Decision Resources, one of ... healthcare issues, finds that sales of agents to treat acute ... increasing from $360 million in 2008 to $450 million in ... United Kingdom and Japan. , The new Pharmacor report entitled ...
... , REYKJAVIK, Iceland, Nov. 17 ... it has filed a voluntary petition for relief under Chapter ... States Bankruptcy Court for the District of Delaware to facilitate ... continuing to operate its business and manage its properties as ...
Cached Medicine Technology:Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 3deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 4
(Date:7/28/2014)... Scottsdale, Ariz (PRWEB) July 28, 2014 ... closed on a new camp property in Cornville, ... provides seriously ill children with the opportunity to ... the campers and families. The organization offers a ... ages 6-15 with chronic and life threatening illnesses ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
(Date:7/28/2014)... Thousands of DePuy Pinnacle hip lawsuits ( ... were allegedly injured by a metal-on-metal version of the ... U.S. District Court, Northern District of Texas, Bernstein Liebhard ... 18, 2014, U.S. District Judge Ed Kinkeade has granted ... Committee that sought the deposition of a witness and ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... are at risk of contracting meningitis because of specific ... to updated recommendations from the largest pediatrician group in ... the potentially deadly infection should continue for adolescents and ... In its first statement on meningococcal vaccines since 2011, ...
(Date:7/28/2014)... there is enough oxygen present to support their offspring, ... this rule. Researchers at The Johns Hopkins University have ... signals, enabling cancers to continue to divide even without ... found that lysosomes the cell,s protein "recycling centers" ... new evidence that certain drugs can halt the growth ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Cell's recycling center implicated in division decisions 2
... oncologist practiced were two factors that strongly influenced the choice ... to an article published April 29 online in the ... IMRT and the cost of radiation therapy increased sharply over ... delivery technique that modulates the radiation beams to conform to ...
... first World Congress of Pediatric Urology was held in San ... successful international congregation of pediatric urologists ever assembled. As part ... and the Journal of Pediatric Urology have together ... The vitality of clinical and basic pediatric urology research was ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, April ... animal of Texas, now has a new claim to fame: ... the bacterium that causes leprosy, and have somehow passed the ... "We,ve confirmed a long-suspected link between leprosy in ...
... 28 (HealthDay News) -- A new study helps confirm ... can greatly diminish quality of life. Researchers analyzed data ... Behavioral Risk Factor Surveillance System survey in 2003, 2005 ... percent of respondents with arthritis compared to 12 percent of ...
... HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) -- ... likely to be more severe than having one at any other ... if the heart attack happens between 6 a.m. and noon, it ... a heart attack occurring in the afternoon or evening, the researchers ...
... autism researchers at the University of California, San Diego School ... promise as a simple way for physicians to detect cases ... babies at an early age. Led by Karen ... of Neurosciences, researchers at the UC San Diego Autism Center ...
Cached Medicine News:Health News:Use of costly breast cancer therapy strongly influenced by reimbursement policy 2Health News:Success of First World Congress of Pediatric Urology underscores increasing importance of specialty 2Health News:Armadillos Give Leprosy to Humans in Southern U.S.: Study 2Health News:Armadillos Give Leprosy to Humans in Southern U.S.: Study 3Health News:Study Highlights Arthritis' Toll on Quality of Life 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 3Health News:Catching signs of autism early: The 1-year well-baby check-up approach 2
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
An injectable IOL, single-use injector for the IOL and post-op protective eye-shield all packaged in one handy, ready-to-use system pack....
... Hydroview™ hydrophilic acrylic IOL is the ... truly designed with the patient and surgeon ... a hydrogel optic polymerically crosslinked with PMMA ... use, and excellent visual performance and biocompatibility. ...
Raysoft Foldable Intraocular Lens....
Medicine Products: